SCHEMBL20207313

SCHEMBL20207313

Cc1ccc2c(c1)c(C(=O)NN)nn2C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.46
HTR3A P46098 5/20 0.43
NAMPT P43490 3/20 0.42
ELANE P08246 1/20 0.41
ALDH1A1 P00352 3/20 0.39
NPC1 O15118 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HSD17B10 Q99714 4/20 0.39
CYP3A4 P08684 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
HTR3E A5X5Y0 2/20 0.39
HTR3B O95264 2/20 0.39
HTR3D Q70Z44 2/20 0.39
HTR3C Q8WXA8 2/20 0.39
HPGD P15428 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19538824 0.83 ELANE (0.47) KDM4EHTR3ANAMPTELANEHSD17B10
SCHEMBL10254085 0.81 KDM4E (0.45) KDM4EHTR3ANAMPTELANEALDH1A1
SCHEMBL31584561 0.81 ELANE (0.51) KDM4EHTR3ANAMPTELANEALDH1A1
SCHEMBL6588422 0.80 KDM4E (0.68) KDM4EHTR3AALDH1A1HDAC3HDAC1
SCHEMBL17445843 0.77 NAMPT (0.40) KDM4EHTR3ANAMPTELANEALDH1A1
SCHEMBL92610 0.76 LMNA (0.43) KDM4ENPC1TSHRL3MBTL1POLB
SCHEMBL12787990 0.73 CYP1A2 (0.56) KDM4EALDH1A1NPC1CYP3A4TSHR
SCHEMBL92606 0.73 LMNA (0.42) KDM4EALDH1A1POLBTDP1LMNA
SCHEMBL12326828 0.71 TDP1 (0.40) KDM4ENAMPTALDH1A1NPC1HSD17B10
SCHEMBL91590 0.70 ALDH1A1 (0.55) KDM4EELANEALDH1A1NPC1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11046680-B1 Heteroaryl-substituted triazoles as APJ receptor agonists AMGEN INC. (US) 2021-06-29 US disclosed
US-11046680-B1 Heteroaryl-substituted triazoles as APJ receptor agonists AMGEN INC. (US) 2021-06-29 US disclosed
EP-3541805-B1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS AMGEN INC (US) 2020-10-14 EP disclosed
EP-3541805-B1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS AMGEN INC (US) 2020-10-14 EP disclosed
WO-2018097945-A1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS AMGEN INC. (US) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046680-B1 Heteroaryl-substituted triazoles as APJ receptor agonists AGTR1, AGTR2, TBXA2R KDM4E 4398/4885HTR3A 234/4885NAMPT 3885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.